Canadians with Waldenström’s Macroglobulinemia who meet inclusion requirements may want to consider participation in a new study of Beigene’s BGB-16673, a Bruton Tyrosine Kinase Targeted Protein Degrader. To help in your understanding of a BTK Degrader, see our recent post comparing them to BTK inhibitors (BTKi).
Official title of the study: A Phase 1/2, Open-Label, Dose Escalation and Expansion Study of the Bruton Tyrosine Kinases Targeted Protein Degrader BGB-16673 in Patients with B-cell Malignancies.
Canadian Study Locations Now Recruiting:
- Calgary, AB: Arthur Child Comprehensive Cancer Centre
- Edmonton, AB: Cross Cancer Institute
- Laval, QC: Université de Laval, Hôpital de l’enfant Jésus, Centre Integre de Cancerologie
- Vancouver, BC: British Columbia Cancer Agency, Vancouver Centre
- Toronto, ON: Princess Margaret Cancer Centre
To learn more, see the trial’s description on the NIH website.